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Background: The increasing and rapid spread of metallo-beta-lactamase (MBL) producing Enterobacteriaceae,
particularly Escherichia coli and Klebsiella pneumoniae represents an emerging public health threat. However, limited
data is available on MBL production in clinical isolates of E. coli and K. pneumoniae from Nepal. We have therefore
undertaken this study to ascertain the incidence of MBL production in clinical isolates of E. coli and K. pneumoniae
at a tertiary care teaching hospital in central Nepal.
Methods: A total of 401 consecutive, non-duplicate isolates of E. coli (n = 216) and K. pneumoniae (n = 185) were
recovered from various clinical samples between July and December, 2012. These isolates were screened for the
detection of carbapenemase production on the basis of their reduced susceptibility to meropenem or ertapenem by
the disc diffusion method. The screened isolates were further phenotypically studied for carbapenemase production by
modified Hodge test (MHT). MBL production was detected by performing combined disc test by using imipenem discs
with and without ethylenediaminetetraacetic acid (EDTA), which chelates zinc required for MBL activity.
Results: Out of 216 E. coli isolates, a total of 41 isolates (18.98%) and out of 185 K. pneumoniae isolates, a total of 39
isolates (21.08%) were suspected to be carbapenemase- producers on the basis of their reduced susceptibility to
meropenem or ertapenem. Interestingly, all the initially suspected isolates of E. coli and K. pneumoniae for carbapenemase
production were found to be positive in both MHT and combined disc test. However, few weakly positive reactions were
observed in MHT. All the MBL producing isolates were multidrug-resistant (MDR). In addition, 75.60% E. coli and 71.79% of
K. pneumoniae isolates producing MBL were found to be “pandrug- resistant”.
Conclusions: Our findings showed MBL production in a considerable number of E. coli and K. pneumoniae isolates with
MDR and pandrug-resistant phenotypes. Combined disc method can provide a sensible choice for phenotypic detection
of MBL production in clinical microbiology laboratories as detection of MBL in bacterial isolates is indispensable for
establishing the effective antibiotic policies and infection control strategies in the hospital setting.
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Pandrug-resistantBackground
Over the past few years, metallo-beta-lactamase (MBL)
producing gram negative bacteria are being reported with
increasing frequency from several parts of the world
and have emerged as a most widespread and clinically
significant carbapenem resistance mechanisms [1]. MBL
producing bacteria can hydrolyze a wide range of beta-* Correspondence: arijitbora07@gmail.com
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unless otherwise stated.lactam antibiotics including penicillins, cephalosporins,
carbapenems, cephamycins, but lack the ability to hydro-
lyze aztreonam. Moreover, their catalytic activities are
generally not neutralized by commercially available β-
lactamase inhibitors such as clavulanate, tazobactam,
and sulbactam [2]. These enzymes belong to Ambler class
B beta-lactamases based on their amino acid sequence
homology and to group 3 according to the Bush classi-
fication based on their substrate and inhibitor profiles
[3,4]. MBLs require zinc-ions to catalyze the hydrolysisd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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on zinc-ions, MBL catalysis is inhibited in presence of
metal-chelating agents like ethylenediaminetetraacetic
acid (EDTA) [5].
MBLs are encoded either by genes that are part of the
chromosome in some bacterial species (resident MBLs),
or by heterologous genes acquired by horizontal gene
transfer (acquired MBLs) [6]. The more geographically
widespread MBLs include imipenemase (IMP), Verona
integron-encoded metallo-beta-lactamase (VIM), and New
Delhi metallo-beta-lactamase (NDM) [5]. MBLs were
common in Pseudomonas aeruginosa and Acinetobacter
spp., but more recently have emerged at an increasing
rate among the members of Enterobacteriaceae [7].
Although, production of MBLs in clinical isolates rep-
resent a serious therapeutic challenge, till date clinical
data are surprisingly inadequate with regard to their
incidence in the members of Enterobacteriaceae, par-
ticularly from Nepal. This prompted us to conduct the
present study to determine the incidence of MBL produc-
tion phenotypically among the isolates of two important
members of Enterobacteriaceae, Escherichia coli and
Klebsiella pneumoniae as well as their antibiotic sus-
ceptibility pattern to formulate an antimicrobial policy
on the basis of the local epidemiological data.
Methods
Bacterial isolates
A total of 401 consecutive, non-duplicate isolates of E. coli
(n = 216) and K. pneumoniae (n = 185) were recovered
from various clinical samples in clinical microbiology
laboratory of College of Medical Sciences, a tertiary care
1050-bed teaching hospital in central Nepal. Samples
were obtained from the hospitalized patients of differ-
ent hospital units between July and December, 2012.
Distribution of the sources of these isolates was: urine
(n = 275), sputum (n = 62), pus (n = 39) and blood (n = 25).
The samples were processed for isolation and identifica-
tion based on standard laboratory techniques [8]. This
study was carried out with consent from the Institutional
Review Committee (IRC) of College of Medical Sciences,
Bharatpur, Nepal.
Antimicrobial susceptibility testing
Antimicrobial sensitivity testing was performed on
Mueller-Hinton agar (MHA) plates by Kirby-Bauer disc
diffusion method, according to Clinical Laboratory Stan-
dards Institute (CLSI) guidelines [9]. The antibiotics used
were: ampicillin (10 μg), cephalexin (30 μg), cefotaxime
(30 μg), ceftazidime (30 μg), cefpodoxime (10 μg), ceftriax-
one (30 μg), cefepime (30 μg), aztreonam (30 μg), cefoxitin
(30 μg), piperacillin/tazobactam (100/10 μg), imipenem
(10 μg), meropenem (10 μg), ertapenem (10 μg), co-trimox-
azole (25 μg), ciprofloxacin (5 μg), levofloxacin (5 μg),gentamicin (10 μg), amikacin (30 μg), tigecycline (15 μg)
and colistin (10 μg). All the antibiotic discs and the media
were procured from Hi-media, Mumbai, India. E. coli
ATCC 25922 was used as quality controls in antibiotic
susceptibility testing. The results were interpreted as per
CLSI guidelines [9] except, tigecycline and colistin. The
results for colistin were interpreted by following the
criteria proposed by Galani et al. [10] and for tigecycline
by following the breakpoints for Enterobacteriaceae as
suggested by Food and Drug Administration (FDA).
The minimum inhibitory concentration (MIC) values
for imipenem, meropenem, ertapenem, tigecycline and
colistin were determined by using Etest strips (bioMerieux,
France) as per the manufacturer’s protocol.
Screening for carbapenemase production
By disc diffusion, each of the isolate with a reduced sus-
ceptibility to meropenem or ertapenem (inhibition zone
diameter of ≤21 mm) was screened for the production of
carbapenemase according to the CLSI guidelines [9].
Detection of carbapenemase production
The phenotypic detection of the carbapenemase produc-
tion was performed by the modified Hodge test (MHT) as
described by CLSI [9]. Briefly, a 0.5 McFarland standard
suspension of E. coli ATCC 25922 was prepared in 5 ml
peptone water and diluted 1:10 by adding 0.5 ml of the 0.5
McFarland to 4.5 ml of peptone water. A lawn of the 1:10
dilution of E. coli ATCC 25922 was prepared on a MHA
plate as for the routine disc diffusion procedure. The plate
was allowed to dry 3 to 10 minutes. A 10 μg ertapenem
disc was placed in the centre of the test plate and the test
organism was streaked in a straight line from the edge of
the disc to the edge of the plate. Three organisms were
tested on the same plate with one drug. The plate was
incubated at 37°C in ambient air for 16–24 hours. After
incubation, a positive MHT test was indicated by a clover
leaf-like indentation of the E. coli ATCC 25922 growing
along the test organism growth streak within the disc
diffusion zone and a negative MHT test was indicated by
no growth of the E. coli ATCC 25922 along the test organ-
ism growth streak within the disc diffusion zone (Figure 1).
Detection of metallo-beta-lactamase production
MBL production was detected by performing combined
disc test described by Franklin et al. [11] in all carbapene-
mase screening positive isolates. In this test, two imipenem
discs (10 μg), one containing 10 μl of 0.1 M (292 μg) anhyd-
rous EDTA (Sigma Chemicals, St. Louis, MO) were used.
They were placed on a MHA plate inoculated with 0.5
McFarland suspension of the test isolate. Plates were
incubated for 16–18 hours at 35°C. After incubation, the
diameter of inhibition zones was measured. An increase in
zone diameter of >4 mm around the imipenem-EDTA
Figure 1 Modified Hodge test using a 10 μg ertapenem disc.
Isolates 1 and 2 produce carbapenemase and are positive by this test.
Isolate 2 does not produce carbapenemase and is negative by this test.
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considered positive for MBL production (Figure 2).
E. coli strain NDM-1 EC27 (positive for NDM-1; kindly
provided by Prof. Giasuddin Ahmed) was used as positive
control in MHT and combined disc test. E. coli ATCC
25922 was used as negative control for both the tests.
Results
Out of 216 E. coli isolates, a total of 41 isolates (18.98%)
and out of 185K. pneumoniae isolates, a total of 39 iso-
lates (21.08%) were initially screened for carbapenemaseFigure 2 Positive combined disc test for detection of MBL
producer by use of EDTA. The test isolate shows a zone diameter
of >4 mm around the imipenem-EDTA disc compared to that of the
imipenem disc alone.production on the basis of their reduced susceptibility to
meropenem or ertapenem by disc diffusion test. All the
screening positive isolates of E. coli and K. pneumoniae
were found to be positive for carbapenemase production
by MHT. However, 3 (7.31%) isolates of E. coli and 4
(10.26%) isolates of K. pneumoniae gave weakly positive
reactions in MHT. Interestingly, all the screening posi-
tive isolates of E. coli and K. pneumoniae showed fairly
positive results in combined disc test for MBL produc-
tion. The age of the patients with MBL positive isolates
ranged from 10 days to 72 years and the male to female
ratio was 1.15:1.
Among the MBL positive isolates of E. coli, 53.56%
(22/41) isolates were recovered from the patients admitted
to intensive care units (ICU) and 46.34% (19/41) isolates
were recovered from the patients admitted to different
hospital wards (Figure 3). Likewise, among the MBL posi-
tive isolates of K. pneumoniae, 58.97% (23/39) isolates
were recovered from the patients admitted to ICU and
46.15% (18/39) isolates were recovered from the patients
admitted to different hospital wards (Figure 3). Sample-
wise distribution of MBL producing isolates of E. coli and
K. pneumoniae are shown in Figure 4.
By disc diffusion susceptibility testing, each of the MBL
producing isolate of E. coli and K. pneumoniae was found
to be resistant to all beta-lactam antibiotics including
imipenem, meropenem, ertapenem, aztreonam as well
as beta-lactam/beta-lactamase combination used in this
study. Susceptibility pattern of these isolates differed
with different classes of non- beta-lactam antibiotics
(Table 1). All the MBL producing isolates are found to
be multidrug-resistant (MDR) i.e., resistant to three or
more classes of antimicrobials. In addition, 75.60% of MBL
producing E. coli isolates and 71.79% of K. pneumoniae
MBL producing E. coli isolates were “pandrug- resistant”
i.e., resistant to 7 antimicrobial agents (cefepime, ceftazi-
dime, imipenem, meropenem, piperacillin/tazobactam,
ciprofloxacin, and levofloxacin). However, each of theFigure 3 Distribution of MBL producing isolates of E. coli and
K. pneumoniae in different hospital units.
Figure 4 Sample-wise distribution of MBL producing isolates of
E. coli and K. pneumoniae.
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found to be sensitive to tigecycline and colistin by disc
diffusion test. The MIC values of MBL producing E. coli
and K. pneumoniae isolates were found to vary widely for
the different carbapenems used in the study (Table 2). AllTable 1 In vitro susceptibility pattern of MBL producing and
by disc diffusion test
Antibiotics tested E. coli (n = 216)
Non-MBL producer (n = 175) MBL produce
Ampicillin (10 μg) 2.85 0.00
Cephalothin (30 μg) 16.57 0.00
Cefpodoxime (10 μg) 35.42 0.00
Ceftazidime (30 μg) 40.57 0.00
Cefotaxime (30 μg) 38.85 0.00
Ceftriaxone (30 μg) 43.42 0.00
Cefepime (30 μg) 46.85 0.00
Aztreonam (30 μg) 40.0 0.00




Imipenem (10 μg) 100.00 0.00
Meropenem (10 μg) 100.00 0.00
Ertapenem (10 μg) 100.00 0.00
Ciprofloxacin (5 μg) 64.00 7.31
Levofloxacin (5 μg) 85.14 24.39
Co-Trimoxazole 61.14 0.00
Gentamicin (10 μg) 72.57 17.07
Amikacin (30 μg) 80.57 21.95
Tigecycline (15 μg) 100.00 100.00
Colistin (10 μg) 100.00 100.00MBL producing isolates showed MIC values in effective
range for tigecycline and colistin.
Discussion
The increasing and rapid spread of MBL producing
Enterobacteriaceae, particularly E. coli and K. pneumoniae
constitutes a serious threat to public health worldwide.
The present study indicated a high incidence of MBL
producing E. coli (18.98%) and K. pneumoniae (21.08%)
in different clinical samples. A previous study from an
another tertiary care hospital in Nepal reported compara-
tively lower incidence of MBL producing gram negative
bacteria (1.3%) in lower respiratory tract specimens [12].
However, a recent study from Nepal addressed the issue
of increasing incidence of MBL producing K. pneumoniae
(18.2%) in tracheal aspirate samples [13]. Several recent
studies from other parts of Asia also demonstrated
increasing incidence of MBL production in Enterobacteri-
aceae isolates [14-16]. In general, production of MBL in
Enterobacteriaceae isolates currently follows an increasing
prevalence pattern and the prevalence rate may vary
greatly in different geographical areas and from institute
to institute. In our hospital setting, extended spectrumnon-MBL-producing isolates of E. coli and K. pneumoniae
% sensitive
K. pneumoniae (n = 185)

























Imipenem Meropenem Ertapenem Tigecycline Colistin
E. coli 2.0 − 8.0 3.0 − 16 8.0− > 32 0.125 − 0.75 0.125 − 0.5
K. pneumoniae 2.0− >32 2.0− >32 6.0− >32 0.38 − 2.0 0.125 − 0.5
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isolates and there is a gradual rise in the use of carba-
penems, which could be a major cause of MBL-
mediated resistant.
The majority of MBL producing isolates of E. coli
(53.56%) and K. pneumoniae (58.97%) were from patients
admitted to ICU. The ICU has been described as a factory
for creating, disseminating, and amplifying antimicrobial
resistance [17]. Among the four different sources of sam-
ples (urine, sputum, pus and blood), we observed highest
incidence of MBL producing isolates in blood samples
and lowest incidence in urine samples for the both patho-
gens. This observation also indicated the greater use of
carbapenems in bloodstream infections in our setting.
Detection methods for carbapenemase production in-
clude MHT, double disc test, blood agar combined disc
assay, PCR amplification, and DNA sequencing [18]. CLSI
recommends the MHT as a phenotypic confirmatory
test for detection of carbapenemase production in
Enterobacteriaceae isolates with elevated MICs for
carbapenems or reduced inhibition zones in disc diffu-
sion susceptibility testing, due to its acceptable sensitivity
and specificity for carbapenemase detection. However, the
sensitivity and the specificity of this test for detecting
low-level MBL production are not known [9]. In this
study, out of 80 E. coli and K. pneumoniae isolates
initially screened for carbapenemase production, 73
(91.25%) isolates exhibited fairly positive results in MHT,
whereas 7 (8.75%) isolates exhibited weakly positive results
in MHT. Different studies also reported the occurrence of
weakly positive results for the MHT in the detection of
MBL producing Enterobacteriaceae [19,20].
On the other hand, the combined disc test performed to
detect MBL production was found to be highly sensitive
(100%) as this test showed positive results with all the iso-
lates of E. coli and K. pneumoniae, which were initially
screened for carbapenemase production by disc diffusion
test. The difference in the zone diameter was fairly more
than 4 mm for each of isolate tested by combined disc
test. Franklin et al. [11] also reported 100% sensitivity
of combined disc test in the detection of MBL in gram
negative bacilli. These results suggest that combined disc
test can be used as a convenient method for detection
of MBL producing E. coli and K. pneumoniae isolates in
clinical laboratory on a daily basis. Conversely, the com-
bined disc test would not detect class A carbapenemases
such as GES, KPC and SME, while the MHT would do so.Besides, molecular detection of carbapenemase genes is
an interesting alternative but remains costly and requires
substantial expertise.
MBL producing bacterial isolates can confer resistance
to carbapenems and all beta-lactam agents except aztreo-
nam although coexistence of other resistance mechanisms
such as AmpC type beta-lactamases or ESBLs render
them resistant to aztreonam [20]. Likewise, all the isolates
of E. coli and K. pneumoniae with MBL production in
the present study were found to be resistant to all three
carbapenems (imipenem, meropenem and ertapenem).
These isolates also exhibited a high level of resistance
to the penicillins, the third and fourth generation ceph-
alosporins, cephamycin, and aztreonam, as well as to the
beta-lactam/beta-lactamase inhibitor combination tested
in the study. These findings are similar with other reports
[21,22], whereas in few reports MBL producing Entero-
bacteriaceae isolates were found to be susceptible to
various carbapenems as well as to piperacillin/tazobactam
by disc diffusion testing [23].
In this study, we observed that MBL production in
E. coli and K. pneumoniae isolates was not always
associated with elevated MIC values for the different
carbapenems tested and these MIC values varied greatly
among the MBL producing isolates. This variation in
the MIC values for the different carbapenems may be
influenced by several factors, such as the type and the
expression of the carbapenemase enzyme, the bacterial
species and the presence of other resistance mechanisms
(e.g., Extended spectrum and AmpC beta-lactamases,
reduced permeability and/or efflux pumps) [24]. Among
the MBL producing isolates, the lowest MIC value for imi-
penem, meropenem and ertapenem were 2 μg/mL, 3 μg/
mL and 8 μg/mL respectively for E. coli and 2 μg/mL,
2 μg/mL and 6 μg/mL respectively for K. pneumoniae iso-
lates. The highest MIC value of >32 μg/mL was observed
for all the three carbapenems in 12.82% MBL producing
isolates of K. pneumoniae. Conversely, 7.3% of MBL
producing isolates of E. coli showed the highest MIC
value of >32 μg/mL only for ertapenem. Carbapenem MICs
for carbapenemase producers may vary within a broad
range of values, and even lay within the susceptibility range,
as defined by either the current CLSI breakpoints. Indeed,
such low levels of resistance to carbapenems have often
been observed in Enterobacteriaceae producing carbapene-
mases of different types [25]. Therefore, any Enterobacteria-
ceae isolate with reduced susceptibility to carbapenems
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carbapenemase production.
It has been observed that carbapenemase producers
are usually associated with many other non beta-lactam
resistance determinants, which give rise to “MDR and
pandrug-resistant” isolates [26]. We also observed 100%
MBL producers as “MDR” as well as 75.60% of E. coli and
71.79% of K. pneumoniae isolates producing MBL were
“pandrug-resistant”. These results highlighted a potential
threat to hospitalized patients by limiting the therapeutic
options. Among the MBL producing isolates, compara-
tively lower resistant rate was for levofloxacin than
ciprofloxacin, amikacin and gentamicin. Different in vitro
studies reveal that tigecycline and colistin are the only
agents with consistent activity against MDR or pan-
resistant MBL-producing isolates [27]. In the present
study, all the MBL producing isolates of E. coli and K.
pneumoniae were also sensitive to tigecycline and colistin
by disc diffusion test and their MIC values were within
the susceptible range. Among these isolates, the MIC
values for colistin ranged from 0.125 − 0.5 μg/mL and for
tigecycline ranged from 0.125‑2.0 μg/mL. However, the
emergence of colistin and tigecycline resistance in Entero-
bacteriaceae is particularly menacing the future treatment
options for bacterial infections [28,29].
Conclusions
Our findings showed MBL production in a considerable
number of E. coli and K. pneumoniae isolates with MDR
and pandrug-resistant phenotypes. In the majority of
hospitalized patients, MBL production in E. coli and
K. pneumoniae is associated with increased mortality,
morbidity and cost. Therefore, early detection of MBL
producing E. coli and K. pneumoniae isolates has become
indispensable for clinical microbiology laboratories. In
absence of molecular detection techniques, the combined
disc test provides a sensible choice for phenotypic detection
of MBL production and can be implemented in clinical
laboratory on a daily basis. In addition, routine surveillance
of MBL producing bacteria is crucial for establishing appro-
priate empirical antimicrobial therapy and restraining their
spread in hospital environment.
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